Olanzapine treatment and metabolic dysfunction: A dose response study in female Sprague Dawley rats

Behavioural Brain Research

Volumn 217, Issue 2, 2011, Pages 337-346

  Weston Green, Katrina ^a,b   Huang, Xu Feng ^a,b   Deng, Chao ^a,b  

^a UNIVERSITY OF WOLLONGONG   (Australia)

^b SCHIZOPHRENIA RESEARCH INSTITUTE   (Australia)

Author keywords

Animal model; Antipsychotic; Dose; Metabolic side effect; Olanzapine; Weight gain

Indexed keywords

CHOLECYSTOKININ; GHRELIN; INSULIN; OLANZAPINE; PEPTIDE YY [3-36];

ABDOMINAL FAT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BROWN ADIPOSE TISSUE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG SAFETY; DRUG SELF ADMINISTRATION; FEMALE; FLUID INTAKE; FOOD INTAKE; HYPERPHAGIA; INSULIN BLOOD LEVEL; LIPID STORAGE; LOCOMOTION; LOW DRUG DOSE; METABOLIC DISORDER; MULTIPLE DRUG DOSE; NONHUMAN; OBESITY; OPEN FIELD TEST; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RAT; SATIETY; SUBCUTANEOUS FAT; TREATMENT DURATION; WEIGHT GAIN;

ADIPOSITY; ANALYSIS OF VARIANCE; ANIMALS; BEHAVIOR, ANIMAL; BENZODIAZEPINES; CHOLECYSTOKININ; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; EATING; EXPLORATORY BEHAVIOR; FEMALE; HORMONES; INTRA-ABDOMINAL FAT; METABOLIC DISEASES; PEPTIDE YY; RATS; RATS, SPRAGUE-DAWLEY; SELF ADMINISTRATION; SEROTONIN UPTAKE INHIBITORS; STATISTICS AS TOPIC; WEIGHT GAIN;

EID: 78650416402     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2010.10.039     Document Type: Article

References (101)

1. Keefe R.S.E., Young C.A., Rock S.L., Purdon S.E., Gold J.M., Breier A. One-year double-blind study of the neurocognitive efficacy of olanzapine, risperidone, and haloperidol in schizophrenia. Schizophrenia Research 2006, 81:1-15.
2. Haro J.M., Novick D., Suarez D., Roca M. Antipsychotic treatment discontinuation in previously untreated patients with schizophrenia: 36-month results from the SOHO study. Journal of Psychiatric Research 2009, 43:265-273.
3. Kane J., Honigfeld G., Singer J., Meltzer H. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Archives of General Psychiatry 1988, 45:789-796.
4. Brown S., Birtwistle J., Roe L., Thompson C. The unhealthy lifestyle of people with schizophrenia. Psychological Medicine 1999, 29:697-701.
5. Allison D.B., Newcomer J.W., Dunn A.L., Blumenthal J.A., Fabricatore A.N., Daumit G.L., et al. Obesity among those with mental disorders: a national institute of mental health meeting report. American Journal of Preventive Medicine 2009, 36:341-350.
6. Lieberman J.A., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. The New England Journal of Medicine 2005, 353:1209-1223.
7. Weston-Green K., Huang X.-F., Han M., Deng C. The effects of antipsychotics on the density of cannabinoid receptors in the dorsal vagal complex of rats: implications for olanzapine-induced weight gain. The International Journal of Neuropsychopharmacology 2008, 11:827-835.
8. Deng C., Weston-Green K., Huang X.-F. The role of histaminergic H1 and H3 receptors in food intake: a mechanism for atypical antipsychotic-induced weight gain?. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2010, 34:1-4.
9. Deng C., Weston-Green K.L., Han M., Huang X.-F. Olanzapine treatment decreases the density of muscarinic M2 receptors in the dorsal vagal complex of rats. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2007, 31:915-920.
10. Han M., Deng C., Burne T.H.J., Newell K.A., Huang X.-F. Short- and long-term effects of antipsychotic drug treatment on weight gain and H1 receptor expression. Psychoneuroendocrinology 2008, 33:569-580.
11. Huang X.-F., Han M., Huang X., Zavitsanou K., Deng C. Olanzapine differentially affects 5-HT2A and 2C receptor mRNA expression in the rat brain. Behavioural Brain Research 2006, 171:355-362.
12. Huang X.F., Deng C., Zavitsanou K. Neuropeptide Y mRNA expression levels following chronic olanzapine, clozapine and haloperidol administration in rats. Neuropeptides 2006, 40:213-219.
13. Kluge M., Schuld A., Schacht A., Himmerich H., Dalal M.A., Wehmeier P.M., et al. Effects of clozapine and olanzapine on cytokine systems are closely linked to weight gain and drug-induced fever. Psychoneuroendocrinology 2009, 34:118-128.
14. Yang L.-H., Chen T.-M., Yu S.-T., Chen Y.-H. Olanzapine induces SREBP-1-related adipogenesis in 3T3-L1 cells. Pharmacological Research 2007, 56:202-208.
15. Coccurello R., Moles A. Potential mechanisms of atypical antipsychotic-induced metabolic derangement: clues for understanding obesity and novel drug design. Pharmacology & Therapeutics 2010, 127:210-251.
16. Reynolds G.P., Kirk S.L. Metabolic side effects of antipsychotic drug treatment-pharmacological mechanisms. Pharmacology & Therapeutics 2010, 125:169-179.
17. Allison D., Mentore J., Heo M., Chandler L., Cappelleri J., Infante M., et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. The American Journal of Psychiatry 1999, 156:1686-1696.
18. Zipursky R.B., Gu H., Green A.I., Perkins D.O., Tohen M.F., McEvoy J.P., et al. Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol. British Journal of Psychiatry 2005, 187:537-543.
19. Zhang Z.-J., Yao Z.-J., Liu W.E.N., Fang Q.U.N., Reynolds G.P. Effects of antipsychotics on fat deposition and changes in leptin and insulin levels: magnetic resonance imaging study of previously untreated people with schizophrenia. British Journal of Psychiatry 2004, 184:58-62.
20. Eder U., Mangweth B., Ebenbichler C., Weiss E., Hofer A., Hummer M., et al. Association of olanzapine-induced weight gain with an increase in body fat. The American Journal of Psychiatry 2001, 158:1719.
21. Graham K.A., Perkins D.O., Edwards L.J., Barrier R.C., et al. Effect of olanzapine on body composition and energy expenditure in adults with first-episode psychosis. The American Journal of Psychiatry 2005, 162:118.
22. Oriot P., Feys J., Mertens de Wilmars S., Misson S., Ayache A., Fagnart O., et al. Insulin sensitivity, adjusted beta-cell function and adiponectinaemia among lean drug-naive schizophrenic patients treated with atypical antipsychotic drugs: a nine-month prospective study. Diabetes & Metabolism 2008, 34:490-496.
23. Perez-Iglesias R., Vazquez-Barquero J.L., Amado J.A., Berja A., Garcia-Unzueta M.T., Pelayo-Teran J.M., et al. Effect of antipsychotics on peptides involved in energy balance in drug-naive psychotic patients after 1 year of treatment. Journal of Clinical Psychopharmacology 2008, 28:289-295.
24. Albaugh V., Henry C., Bello N., Hajnal A., Lynch S., Halle B., et al. Hormonal and metabolic effects of olanzapine and clozapine related to body weight in rodents. Obesity 2006, 14:36-50.
25. Houseknecht K.L., Robertson A.S., Zavadoski W., Gibbs E.M., Johnson D.E., Rollema H. Acute effects of atypical antipsychotics on whole-body insulin resistance in rats: implications for adverse metabolic effects. Neuropsychopharmacology 2006, 32:289-297.
26. Boyda H.N., Tse L., Procyshyn R.M., Wong D., Wu T.K.Y., Pang C.C., et al. A parametric study of the acute effects of antipsychotic drugs on glucose sensitivity in an animal model. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2010, 34:945-954.
27. Vidarsdottir S., Roelfsema F., Streefland T., Holst J.J., Rehfeld J.F., Pijl H. Short-term treatment with olanzapine does not modulate gut hormone secretion: olanzapine disintegrating versus standard tablets. European Journal of Endocrinology 2010, 162:75-83.
28. Tanaka K., Morinobu S., Ichimura M., Asakawa A., Inui A., Hosoda H., et al. Decreased levels of ghrelin, cortisol, and fasting blood sugar, but not n-octanoylated ghrelin, in Japanese schizophrenic inpatients treated with olanzapine. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2008, 32:1527-1532.
29. Atmaca M., Tezcan E., Ustundag B. Plasma nitric oxide and leptin values in patients with olanzapine-induced weight gain. Journal of Psychiatric Research 2007, 41:74-79.
30. Esen-Danaci A., Sarandöl A., Taneli F., Yurtsever F., Özlen N. Effects of second generation antipsychotics on leptin and ghrelin. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2008, 32:1434-1438.
31. Jin H., Meyer J.M., Mudaliar S., Jeste D.V. Impact of atypical antipsychotic therapy on leptin, ghrelin, and adiponectin. Schizophrenia Research 2008, 100:70-85.
32. Gebhardt S., Haberhausen M., Heinzel-Gutenbrunner M., Gebhardt N., Remschmidt H., Krieg J.-C., et al. Antipsychotic-induced body weight gain: predictors and a systematic categorization of the long-term weight course. Journal of Psychiatric Research 2009, 43:620-626.
33. Sentissi O., Epelbaum J., Olie J.-P., Poirier M.-F. Leptin and ghrelin levels in patients with schizophrenia during different antipsychotics treatment: a review. Schizophrenia Bulletin 2008, 34:1189-1199.
34. Choi S., DiSilvio B., Unangst J., Fernstrom J.D. Effect of chronic infusion of olanzapine and clozapine on food intake and body weight gain in male and female rats. Life Sciences 2007, 81:1024-1030.
35. Minet-Ringuet J., Even P.C., Goubern M., Tomé D., de Beaurepaire R. Long term treatment with olanzapine mixed with the food in male rats induces body fat deposition with no increase in body weight and no thermogenic alteration. Appetite 2006, 46:254-262.
36. Minet-Ringuet J., Even P.C., Guesdon B., Tomé D., de Beaurepaire R Effects of chronic neuroleptic treatments on nutrient selection, body weight, and body composition in the male rat under dietary self-selection. Behavioural Brain Research 2005, 163:204-211.
37. Pouzet B., Mow T., Kreilgård M., Velschow S. Chronic treatment with antipsychotics in rats as a model for antipsychotic-induced weight gain in human. Pharmacology, Biochemistry and Behavior 2003, 75:133-140.
38. Ota M., Mori K., Nakashima A., Kaneko Y., Fujiwara K., Itoh M., et al. Peripheral injection of risperidone, an atypical antipsychotic, alters the bodyweight gain of rats. Clinical and Experimental Pharmacology and Physiology 2002, 29:980-989.
39. Thornton-Jones Z., Neill J.C., Reynolds G.P. The atypical antipsychotic olanzapine enhances ingestive behaviour in the rat: a preliminary study. Journal of Psychopharmacology 2002, 16:35-37.
40. Hartfield A., Moore N., Clifton P Effects of clozapine, olanzapine and haloperidol on the microstructure of ingestive behaviour in the rat. Psychopharmacology 2003, 167:115.
41. Minet-Ringuet J., Even P., Lacroix M., Tomé D., de Beaurepaire R. A model for antipsychotic-induced obesity in the male rat. Psychopharmacology 2006, 187:447-454.
42. Shobo M., Yamada H., Mihara T., Kondo Y., Irie M., Harada K., et al. Two models for weight gain and hyperphagia as side effects of atypical antipsychotics in male rats: validation with olanzapine and ziprasidone. Behavioural Brain Research 2010, 216:561-568.
43. Schleimer S.B., Johnston G.A.R., Henderson J.M. Novel oral drug administration in an animal model of neuroleptic therapy. Journal of Neuroscience Methods 2005, 146:159-164.
44. Balcombe J., Barnard N., Sandusky C. Laboratory routines cause animal stress. Contemporary Topics in Laboratory Animal Science 2004, 43:42-51.
45. Arjona A.A., Zhang S.X., Adamson B., Wurtman R.J. An animal model of antipsychotic-induced weight gain. Behavioural Brain Research 2004, 152:121-127.
46. Fell M., Marshall K., Williams J., Neill J Effects of the atypical antipsychotic olanzapine on reproductive function and weight gain in female rats. Journal of Psychopharmacology 2004, 18:149-155.
47. Cooper G., Pickavance L., Wilding J., Halford J., Goudie A. A parametric analysis of olanzapine-induced weight gain in female rats. Psychopharmacology 2005, 181:80-89.
48. Aravagiri M., Teper Y., Marder S. Pharmacokinetics and tissue distribution of olanzapine in rats. Biopharmaceutics and Drug Disposition 1999, 20:369-377.
49. du Bois T.M., Huang X.-F., Deng C. Perinatal administration of PCP alters adult behaviour in female Sprague-Dawley rats. Behavioural Brain Research 2008, 188:416-419.
50. Goudie A., Smith J., Halford J. Characterization of olanzapine-induced weight gain in rats. Journal of Psychopharmacology 2002, 16:291-296.
51. Kalinichev M., Rourke C., Daniels A., Grizzle M., Britt C., Ignar D., et al. Characterisation of olanzapine-induced weight gain and effect of aripiprazole vs olanzapine on body weight and prolactin secretion in female rats. Psychoparmacology 2005, 182:220-231.
52. Cope M.B., Nagy T.R., Fernandez J.R., Geary N., Casey D.E., Allison D.B. Antipsychotic drug-induced weight gain: development of an animal model. International Journal of Obesity and Related Metabolic Disorders 2005, 29:607-614.
53. Coccurello R., Caprioli A., Conti R., Ghirardi O., Borsini F., Carminati P., et al. Olanzapine (LY170053, 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5] benzodiazepine), but not the novel atypical antipsychotic ST2472 (9-piperazin-1-ylpyrrolo[2,1-b][1,3]benzothiazepine), chronic administration induces weight gain, hyperphagia, and metabolic dysregulation in mice. Journal of Pharmacology & Experimental Therapeutics 2008, 326:905-911.
54. Nasrallah H. A review of the effect of atypical antipsychotics on weight. Psychoneuroendocrinology 2003, 28:83-96.
55. Nemeroff C. Dosing the antipsychotic medication olanzapine. Journal of Clinical Psychiatry 1997, 58:45-49.
56. Gothelf D., Falk B., Singer P., Kairi M., Phillip M., Zigel L., et al. Weight gain associated with increased food intake and low habitual activity levels in male adolescent schizophrenic inpatients treated with olanzapine. American Journal of Psychiatry 2002, 159:1055-1057.
57. Stefanidis A., Verty A.N.A., Allen A.M., Owens N.C., Cowley M.A., Oldfield B.J. The role of thermogenesis in antipsychotic drug-induced weight gain. Obesity 2009, 17:16-24.
58. Coccurello R, Brina D, Caprioli A, Conti R, Ghirardi O, Schepis F, et al. Days of continuous olanzapine infusion determines energy imbalance, glucose intolerance, insulin resistance, and dyslipidemia in mice. Journal of Clinical Psychopharmacology 2009;29:576-83. 510.1097/JCP.1090b1013e3181bfe1013e.
59. Patil B., Kulkarni N., Unger B. Elevation of systolic blood pressure in an animal model of olanzapine induced weight gain. European Journal of Pharmacology 2006, 551:112-115.
60. de Leon J., Verghese C., Josiassen R., Simpson G. Polydipsia and water intoxication in psychiatric patients: a review of the epidemiological literature. Biological Psychiatry 1994, 35:519-530.
61. Lee H., Kwon K., Alphs L., Meltzer H. Effect of clozapine on psychogenic polydipsia in chronic schizophrenia. Journal of Clinical Psychopharmacology 1991, 11:222.
62. Goldman M.B., Hussain N. Absence of effect of olanzapine on primary polydipsia: results of a double-blind, randomized study. Journal of Clinical Psychopharmacology 2004, 24:678-680.
63. Chintoh A.F., Mann S.W., Lam T.K.T., Giacca A., Remington G. Insulin resistance following continuous, chronic olanzapine treatment: an animal model. Schizophrenia Research 2008, 104:23-30.
64. Schwartz M.W., Woods S.C., Porte D., Seeley R.J., Baskin D.G. Central nervous system control of food intake. Nature 2000, 404:661-671.
65. Chiu C., Chen K., Liu H., Lu M. The early effect of olanzapine and risperidone on insulin secretion in atypical-naive schizophrenic patients. Journal of Clinical Psychopharmacology 2006, 26:504-507.
66. Chintoh A.F., Mann S.W., Lam L., Lam C., Cohn T.A., Fletcher P.J., et al. Insulin resistance and decreased glucose-stimulated insulin secretion after acute olanzapine administration. Journal of Clinical Psychopharmacology 2008, 28:494-499.
67. Wu R., Zhao J., Guo X., He Y., Fang M., Guo W., et al. Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study. American Journal of Psychiatry 2008, 165:352-358.
68. Chiu C.-C., Chen C.-H., Chen B.-Y., Yu S.-H., Lu M.-L. The time-dependent change of insulin secretion in schizophrenic patients treated with olanzapine. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2010, 34:866-870.
69. Bymaster F.P., Nelson D.L., DeLapp N.W., Falcone J.F., Eckols K., Truex L.L., et al. Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and [alpha]1-adrenergic receptors in vitro. Schizophrenia Research 1999, 37:107-122.
70. Johnson D.E., Yamazaki H., Ward K.M., Schmidt A.W., Lebel W.S., Treadway J.L., et al. Inhibitory effects of antipsychotics on carbachol-enhanced insulin secretion from perifused rat islets: role of muscarinic antagonism in antipsychotic-induced diabetes and hyperglycemia. Diabetes 2005, 54:1552-1558.
71. Balakrishnan S., Mathew J., Antony S., Paulose C.S. Muscarinic M1, M3 receptors function in the brainstem of streptozotocin induced diabetic rats: their role in insulin secretion from the pancreatic islets as a function of age. European Journal of Pharmacology 2009, 608:14-22.
72. Renuka T.R., Ani D.V., Paulose C.S. Alterations in the muscarinic M1 and M3 receptor gene expression in the brain stem during pancreatic regeneration and insulin secretion in weanling rats. Life Sciences 2004, 75:2269-2280.
73. Murashita M., Kusumi I., Hosoda H., Kangawa K., Koyama T. Acute administration of clozapine concurrently increases blood glucose and circulating plasma ghrelin levels in rats. Psychoneuroendocrinology 2007, 32:777-784.
74. Murashita M., Kusumi I., Inoue T., Takahashi Y., Hosoda H., Kangawa K., et al. Olanzapine increases plasma ghrelin level in patients with schizophrenia. Psychoneuroendocrinology 2005, 30:106-110.
75. Kim B.-J., Sohn J.-W., Park C.-S., Hahn G.-H., Koo J., Noh Y.-D., et al. Body weight and plasma levels of ghrelin and leptin during treatment with olanzapine. Journal of Korean Medical Science 2008, 23:685-690.
76. Hosojima H., Togo T., Odawara T., Hasegawa K., Miura S., Kato Y., et al. Early effects of olanzapine on serum levels of ghrelin, adiponectin and leptin in patients with schizophrenia. Journal of Psychopharmacology 2006, 20:75-79.
77. Popovic V., Doknic M., Maric N., Pekic S., Damjanovic A., Miljic D., et al. Changes in neuroendocrine and metabolic hormones induced by atypical antipsychotics in normal-weight patients with schizophrenia. Neuroendocrinology 2007, 85:249-256.
78. Berridge K.C., Peciña S. Benzodiazepines, appetite, and taste palatability. Neuroscience and Biobehavioral Reviews 1995, 19:121-131.
79. Hiejima H., Nishi Y., Hosoda H., Yoh J., Mifune H., Satou M., et al. Regional distribution and the dynamics of n-decanoyl ghrelin, another acyl-form of ghrelin, upon fasting in rodents. Regulatory Peptides 2009, 156:47-56.
80. Orr J., Davy B. Dietary influences on peripheral hormones regulating energy intake: potential applications for weight management. Journal of the American Dietetic Association 2005, 105:1115-1124.
81. Shrestha Y.B., Wickwire K., Giraudo S.Q. Direct effects of nutrients, acetylcholine, CCK, and insulin on ghrelin release from the isolated stomachs of rats. Peptides 2009, 30:1187-1191.
82. Burdyga G., Lal S., Varro A., Dimaline R., Thompson D.G., Dockray G.J. Expression of Cannabinoid CB1 receptors by vagal afferent neurons is inhibited by cholecystokinin. Journal of Neuroscience 2004, 24:2708-2715.
83. Beinfeld M.C., Garver D.L. Concentration of cholecystokinin in cerebrospinal fluid is decreased in psychosis: relationship to symptoms and drug response. Progress in Neuro-Psychopharmacology and Biological Psychiatry 1991, 15:601-609.
84. Bachus S.E., Hyde T.M., Herman M.M., Egan M.F., Kleinman J.E. Abnormal cholecystokinin mRNA levels in entorhinal cortex of schizophrenics. Journal of Psychiatric Research 1997, 31:233-256.
85. Virgo L., Humphries C., Mortimer A., Barnes T., Hirsch S., de Belleroche J. Cholecystokinin messenger RNA deficit in frontal and temporal cerebral cortex in schizophrenia. Biological Psychiatry 1995, 37:694-701.
86. Batterham R.L., Cohen M.A., Ellis S.M., Le Roux C.W., Withers D.J., Frost G.S., et al. Inhibition of food intake in obese subjects by Peptide YY(3-36). New England Journal of Medicine 2003, 349:941-948.
87. Zwirska-Korczala K., Konturek S., Sodowski M., Wylezol M., Kuka D., Sowa P., et al. Basal and postprandial plasma levels of PYY, ghrelin, cholecystokinin, gastrin and insulin in women with moderate and morbid obesity and metabolic syndrome. Journal of Physiology and Pharmacology 2007, 58:13-35.
88. Wang Q., Huang X.-F. Effects of chronic treatment of olanzapine and haloperidol on peptide YY binding densities in the rat brain. Experimental Neurology 2008, 209:261-267.
89. Beasley J.C.M., Tollefson G., Tran P., Satterlee W., Sanger T., Hamilton S. Olanzapine versus placebo and haloperidol: Acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 1996, 14:111-123.
90. Sharpe J.-K., Byrne N.M., Stedman T.J., Hills A.P. Resting energy expenditure is lower than predicted in people taking atypical antipsychotic medication. Journal of the American Dietetic Association 2005, 105:612-615.
91. Virkkunen M., Wahlbeck K., Rissanen A., Naukkarinen H., Franssila-Kallunki A. Decrease of energy expenditure causes weight increase in olanzapine treatment-a case study. Pharmacopsychiatry 2002, 35(124):126.
92. Procyshyn R.M., Chau A., Tse G. Clozapine's effects on body weight and resting metabolic rate: a case series. Schizophrenia Research 2004, 66:159-162.
93. Cope M.B., Li X., Jumbo-Lucioni P., DiCostanzo C.A., Jamison W.G., Kesterson R.A., et al. Risperidone alters food intake, core body temperature, and locomotor activity in mice. Physiology and Behavior 2009, 96:457-463.
94. Karl T., Duffy L., O'Brien E., Matsumoto I., Dedova I. Behavioural effects of chronic haloperidol and risperidone treatment in rats. Behavioural Brain Research 2006, 171:286-294.
95. Reagan-Shaw S., Nihal M., Ahmad N. Dose translation from animal to human studies revisited. The FASEB Journal 2007, 22:659-661.
96. Cooper G.D., Harrold J.A., Halford J.C.G., Goudie A.J. Chronic clozapine treatment in female rats does not induce weight gain or metabolic abnormalities but enhances adiposity: implications for animal models of antipsychotic-induced weight gain. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2008, 32:428-436.
97. Tulipano G., Rizzetti C., Bianchi I., Fanzani A., Spano P., Cocchi D. Clozapine-induced alteration of glucose homeostasis in the rat: the contribution of hypothalamic-pituitary-adrenal axis activation. Neuroendocrinology 2007, 85:61.
98. Smith G., Chaussade C., Vickers M., Jensen J., Shepherd P. Atypical antipsychotic drugs induce derangements in glucose homeostasis by acutely increasing glucagon secretion and hepatic glucose output in the rat. Diabetologia 2008, 51:2309-2317.
99. Weston-Green K., Huang X.-F., Deng C. Sensitivity of the female rat to olanzapine-induced weight gain--Far from the clinic?. Schizophrenia Research 2010, 116:299-300.
100. Ryan M.C.M., Flanagan S., Kinsella U., Keeling F., Thakore J.H. The effects of atypical antipsychotics on visceral fat distribution in first episode, drug-naive patients with schizophrenia. Life Sciences 2004, 74:1999-2008.
101. van der Zwaal E.M., Luijendijk M.C.M., Evers S.S., la Fleur S.E., Adan R.A.H. Olanzapine affects locomotor activity and meal size in male rats. Pharmacology Biochemistry and Behavior 2010, 97(1):130-137.